A variety of novel quinoline derivatives (6-phenyl-6H-chromeno [4,3-b] quinoline) have been prepared by using 4-chloro-2-phenyl-2H-chromene-3carbaldehyde and various substituted of aromatic anilines as starting materials. This is the first example on the preparation of quinolines through this novel method. And the resulting quinoline derivatives further structure evolution is leads to an anti cancer agents. Our preliminary data of model compound (7i) on three cancer cell lines (B16F10, MCF7 and A549) suggested decent anticancer activity on two cell lines (B16F10 and MCF7) with IC50 values of 14.8 and 21.32 µM, respectively. This method is operationally simple and works with a diverse range of substrates.
The quinoline, chromone, chalcones, flavanones moieties are the basic back bone skeletons occur in the wide range of bioactive natural products, and their derivatives play a broad range of various biological activities such as antimalarial drugs [1] , antihypertensive [2] , antitumor [3] , ATP sensitive potassium channel opener [4] , In other hands quinolines are the moiety which are found particularly in Alkaloids [5] , Quinoline derivatives shows broad range of pharmacological properties such as anticancer [6] , anti Alzheimers activities [7] , antituberculosis [8] , antiretroviral [9] , substituted quinolines, for example combination of flavonones and coumarines with quinolines ( Figure 1 ) structures shows anticancer activity [6] , However they each combination comes under separate classification.
Due to quinolines show an ample range of applications in medicines, agriculture, and industry several methods have been developed for the synthesis of these compounds [10] . The earlier reports have shown harsh reaction conditions, classy availability of the starting materials, expensive reagents and long time duration reaction conditions to maintenance are considerable drawbacks. Hence, we report a novel approach for the synthesis of 6-phenyl-6H-chromeno [4,3-b] quinoline 7(a-p) using 4-chloro-2-phenyl-2Hchromen-3-carbaldehyde 5 and various substituted aromatic anilines 6, These reactions are performed at room temperature, with short term of maintenance reaction conditions to yield excessively, no catalyst has been used in this method which can be considered as commercially viable (Scheme 1).
In continuation of our work [11] , We report the method by using starting material 4-Chloro-2-aryl-2H-3-chromene carbaldehyde 5 prepared from 2-phenyl chroman-4-one 4, through Vilsmeier-Haack reaction [12] , and compound 3 prepared by simple Aldol condensation or Baker-Venkataraman rearrangement [13] (Scheme 2). The Scheme 1: Synthesis of 6-phenyl-6H-chromeno [4,3-b] quinolone. most common synthetic routes to prepare the flavanone 4 occurs via chalcone intermediate or via Baker Venkataraman rearrangement in which chalcone pathway involves the base catalyzed aldol condensation of 2-hydroxyacetophenones 1 with aromatic or conjugated aldehydes 2 in the presence of base. The resulting chalcone 3 cyclized to produce flavanones via Algar-Flym-Oyamada (AFO) reaction [14] .
A Series of 6-phenyl-6H-chromeno [4,3-b] quinoline derivatives 7(a-p) were prepared from 4-Chloro-2-Phenyl-2H-chromene-3-Carbaldehyde, 5 with various aromatic anilines in good yields under catalyst free conditions at room temperature ( Table 1 ). The aromatic anilines contained electron withdrawing and electron donating groups. All examples mentioned in Table 1 were performed easily in short duration of reaction time (~ one hour) when compared to earlier reports. 
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To assess the cytotoxicity profile, we screened 7i as model compound in three different cancer cell lines (B16F10, MCF7 and A549). The representative screened compound showed decent anticancer activity on two of the studied cell lines with IC50 values of 14.8 µM on B16F10 and 21.32 µM on MCF7 cells, whereas A549 human lung carcinoma cells showed higher resistance with IC50 value of 199.85 µM. These results indicate anticancer potential of these series and warrants future investigations for further anticancer drug development. The representative percentage viability graph is shown in Figure 2 . The structures of the above mentioned compounds were further confirmed from their spectroscopic and analytical data.
Scheme 2: Synthesis of starting material 5 via Aldol/Baker Venkataraman rearrangement.
Scheme 3:
The plausible mechanism of the formation of the 6-phenyl-6H-chromeno [4, 3-b] quinoline 7(a-p).
In conclusion, we have developed simple one-pot and efficient catalyst-free quinoline derivatives at RT conditions using 4-chloro-6H-carbaldehydes and different aromatic anilines. The direct conversation to the novel quinoline derivatives in simple and good yields are notable features of the present novel method.
Experimental
Instruments & material Used: IR, spectra were recorded on a Perkin-Elmer RX1 FT-IR spectrometer of samples prepared as KBr pellets. NMR spectra were recorded of samples in CDCl 3 on a Varian Gemini spectrometer operating at 300 MHz ( 1 H NMR) and 400 MHz ( 13 C NMR). MS determinations were carried out by the ESI method on a Waters Alliance mass spectroscopic instrument. Elemental analyses were carried out on an Elementar Vario Micro Cube instrument. Column chromatography was per-formed on silica gel (200-300 mesh).
General preparation Procedure for the synthesis of 6-phenyl-6H-chromeno [4, 3-b] quinoline derivatives 7(a-p):
The appropriate carbaldehyde 7 (1 mmol) and aromatic aniline 6 (1 mmol) were added in a round bottomed flask under nitrogen atmosphere. The resulting mixture was stirred at room temperature for one hour, and the reaction mass checked by (TLC) Thin Layer Chromatography. After completion of the reaction, the mixture was washed with sat. aq NaHCO 3 (3 × 5mL) and subsequently extracted with EtOAc (3 × 5 mL). The extract was concentrated under reduced pressure, and the residue was subjected to column chromatography (silica gel, hexane-EtOAc); to give the corresponding pure quinoline 7(a-p). Catalyst-free synthesis of quinoline derivatives Natural Product Communications Vol. 12 (7) 2017 1131 Figure 2: Cytotoxicity evaluation of model compound (7i) . Three different cancer cell lines (A-B16F10, B-MCF7 and C-A549), were treated with different concentrations of 7i (0.937-30 μM) for 48 h; cell viability was assessed using MTT assay. Data is represented as mean±S.D, carried out in triplicates. ** means significant difference (P < 0.01)., *** means significant difference (P < 0.001) when compared with control (no drug treatment).
(FBS, Gibco, USA), and Penicillin-Streptomycin (100 IU/mL each; Sigma Aldrich, USA), whereas A549 cells were maintained in RPMI-1640 (Sigma Aldrich, USA) media supplemented with FBS and antibiotic mix. The cytotoxicity assay was performed as per MTT (3-(4,5dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide) (Himedia, India) assay protocol as per our established method.
For cytotoxicity evaluation, 96 well plates (Nest, India) were seeded with approximately 5000 cells/well and incubated overnight at 37ºC and 5% CO 2 in a humidified incubator (Eppendorf, Germany). The selected compound was incubated with cells for 48 hours at six different concentrations in triplicates (0.94, 1.88, 3.75, 7.5, 15 and 30 µM) prepared in respective plain media without FBS. After incubation, drug solutions were rinsed and the cells were incubated with 100 µL MTT solution/per well (0.5 mg/mL, prepared in plain media) for 4 hours. Thereafter, the formed formazan crystals were dissolved by adding 200 µL DMSO/well, and kept on orbital shaker for 20 min. Thereafter, the OD was measured at 570 nm and results were quantified for the calculation of IC 50 values using Graphpad Prism, version 5.0. 7.62-7.58 (m, 1H), 7.50-7.40 (m, 1H), 7.48 -7.42 (m, 7H), 7.33 (m, 1H), 7.19 -7.14 (m, 1H) , 7.04 (dd, J = 8.1, 0.8 Hz, 1H), 6.32 (d, J = 0.9 Hz, 1H). 13 C NMR (100 MHz, CDCl 3 ) δ: 156.6, 149.2, 146.4, 138.3, 132.3, 131.9, 131.9, 130.8, 130.6, 129.5, 129.0, 128.9, 128.1, 128.0, 126.4, 125.5, 122.8, 122.7, 117.7, 80.23 5, 148.9, 148.1, 138.7, 132.9, 132.0, 129.8, 129.3, 128.9, 128.8, 128.5, 128.2, 127.8, 127.5, 126.2, 125.6, 123.2, 122.6, 117.7, 80 150.0, 138.0, 134.8, 132.4, 132.2, 132.0, 131.0, 129.6, 129.1, 128.9, 128.2, 126.5, 125.7, 122.1, 120.5, 114.9, 114.7, 114.6, 113.9, 108.9, 55.5. Mass spectrum (ESI) : m/z 400 [M + H] + . Anal. Calcd for C 25 H 21 NO 4 : C, 75.18; H, 5.26; N, 3.50. Found: C, 75.27; H, 5.21; N, 3.56 .
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